GlaxoSmithKline LLC allegedly engaged in unfair and deceptive practices when it misrepresented the safety profile of its diabetes drug, Avandia. As a result of the investigation, GSK has agreed to change the way it markets its diabetes drugs and refrain from any false, misleading or deceptive promotion of its diabetes drugs, which was in violation of the Tennessee Consumer Protection Act. GSK has also agreed to make changes regarding disclosures about clinical research of its diabetes drugs. This was a multistate case.
This list includes only significant filings and is not intended to be a complete record of the matter.